Beam Therapeutics Inc. (NASDAQ:BEAM) shares jumped 12% following the announcement that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation ...

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative ...

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene ...

The Drug Discovery Services Companies Quadrant provides an in-depth analysis of the drug discovery services market, highlighting key players, technological advancements, and trends. Conducted by ...

Beam Therapeutics' said the Food and Drug Administration granted generative medicine advanced therapy designation to its sickle cell disease treatment BEAM-101.

Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELP ...

Soligenix’s (SNGX) dusquetide, a treatment of Behcet’s disease , received FDA orphan designation, according to a post to the agency’s website.